Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem® (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem® 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.
Novo Nordisk introduced Vagifem® 10 mcg to the U.S. market earlier this year. The new dose replaces Vagifem® 25 mcg dose, which was discontinued on July 30, 2010.
"This partnership with Upsher-Smith supports the launch and conversion of the U.S. market to Vagifem® 10 mcg," said Eddie Williams, Vice President of Biopharmaceuticals at Novo Nordisk. "Leveraging Upsher-Smith's experienced sales force, we are able to maintain our commitment to patient care and the medical community by making sure that physicians are aware of Vagifem® 10 mcg for treating menopausal women with symptoms of atrophic vaginitis."
"The alignment of our two organizations and our products, which offer low-dose estrogen treatments for menopausal women, make this a unique partnership opportunity," said Tom Burke, Executive Vice President, Commercial Operations at Upsher-Smith. "The combined history of our two companies offers more than two centuries of experience bringing meaningful pharmaceutical products to the marketplace."
Financial terms of the agreement are not being disclosed.
Research reveals only a few brain regions remain untouched by transition to motherhood